Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.85
-2.0300-3.45%
Volume:2.39M
Turnover:136.81M
Market Cap:5.36B
PE:-119.32
High:59.58
Open:58.64
Low:56.23
Close:58.88
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.64
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:218.53
PE(LYR):-198.53

Loading ...

Travere Therapeutics, Inc. : Wells Fargo Raises Target Price to $65 From $50

THOMSON REUTERS
·
Jun 12

Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo

TIPRANKS
·
Jun 12

Travere Therapeutics grants 32,000 inducement RSUs to six new employees

Reuters
·
Jun 12

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 12

3 Stocks That May Be Priced Below Their Estimated Value In June 2026

Simply Wall St.
·
Jun 09

A Look At Travere Therapeutics (TVTX) Valuation After New Long Term FILSPARI FSGS Data

Simply Wall St.
·
Jun 07

Travere Therapeutics says Filspari generally well tolerated in Phase 3 study

TIPRANKS
·
Jun 04

Travere reports 5-year DUPLEX extension data showing sustained proteinuria reduction with FILSPARI in FSGS

Reuters
·
Jun 04

Travere Therapeutics Presents Long-Term Open-Label Extension Data From the Phase 3 Duplex Study at the 63Rd European Renal Association (Era) 2026 Congress

THOMSON REUTERS
·
Jun 04

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (ELAN), AbSci (ABSI) and Travere Therapeutics (TVTX)

TIPRANKS
·
Jun 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Picard Medical, Inc. (PMI) and Travere Therapeutics (TVTX)

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Reuters
·
Jun 02

Travere Therapeutics enters into exclusive licensing agreement with Everest

TIPRANKS
·
Jun 02

Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines

MT Newswires Live
·
Jun 02

Travere Therapeutics licenses Everest Medicines’ civorebrutinib outside China in USD 112.5 million deal

Reuters
·
Jun 02

Travere Therapeutics - to Pay Tiered Royalties on Future Civorebrutinib Sales

THOMSON REUTERS
·
Jun 02

Travere Therapeutics - Everest to Receive $112.5 Mln Upfront for Civorebrutinib Rights

THOMSON REUTERS
·
Jun 02

Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines for Civorebrutinib a Potential Best-in-Class Btk Inhibitor for Rare Kidney Diseases

THOMSON REUTERS
·
Jun 02

Travere Therapeutics - Everest Eligible for up to $1.03 Bln in Additional Milestone Payments

THOMSON REUTERS
·
Jun 02